Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)

This study has been terminated.
(primary outcome measure not met)
Sponsor:
Information provided by (Responsible Party):
Arbor Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT02074007
First received: January 16, 2014
Last updated: June 23, 2014
Last verified: June 2014
  Purpose

Children ages 2 months to less than 19 years old, who have been diagnosed with a middle ear infection may receive either medicated ear drops (AR01) or glycerin (placebo) ear drops. The patient or caregiver will measure the amount of ear pain before and after the ear drops to establish if the medicated ear drops decrease the amount of pain more than the placebo ear drops. The subject may leave the clinic 60 minutes after the first dose. The ear drops can be used up to 4 days, as needed for ear pain.


Condition Intervention Phase
Acute Otitis Media
Drug: AR01
Drug: Glycerin ear drops
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years

Resource links provided by NLM:


Further study details as provided by Arbor Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Complete ear pain relief [ Time Frame: At or prior to 60 minutes post baseline dose ] [ Designated as safety issue: No ]
    The proportion of subjects with complete pain relief (score of 0 on Face, Activity, Ears, Cry, Consolability tool (FAECC) as measured by the Assigned Clinical Assessor or Faces Pain Scale-Revised (FPS-R) as measured by the subject prior to any analgesic/antipyretic use) at or prior to 60 minutes post baseline dose.


Secondary Outcome Measures:
  • time to complete ear pain relief (score of 0 on pain scales) [ Time Frame: 10, 20, 30, 45, and 60 minutes post baseline dose ] [ Designated as safety issue: No ]
    The time to complete pain relief (score of 0 on FAECC or FPS-R prior to any analgesic/antipyretic use), in minutes.

  • The proportion of subjects with complete ear pain relief [ Time Frame: at or prior to 10, 20, 30, 45, and 60 minutes post baseline dose ] [ Designated as safety issue: No ]
    The proportion of subjects with complete ear pain relief (score of 0 on FAECC or FPS-R prior to any analgesic/antipyretic use) at or prior to 10, 20, 30, 45, and 60 minutes post baseline dose.

  • The percent change in FPS-R and FAECC pain scores from baseline to post dose scores [ Time Frame: measured at 10, 20, 30, 45, and 60 minutes post baseline dose ] [ Designated as safety issue: No ]
  • Sum of pain intensity differences (SPID) using FPS-R and FAECC pain scores [ Time Frame: scores at pre-dose and 60 minutes post dose ] [ Designated as safety issue: No ]
  • Time from baseline to in-clinic use of analgesic/antipyretic to relief ear pain [ Time Frame: 60 minutes ] [ Designated as safety issue: No ]
  • The number of subjects who receive analgesic/antipyretic medications for relief of ear pain during the clinic visit [ Time Frame: measured at or prior to 10, 20, 30, 45, and 60 minutes post baseline ] [ Designated as safety issue: No ]
  • Number of adverse events reported as a measure of safety and tolerability [ Time Frame: up to 30 days ] [ Designated as safety issue: Yes ]

Other Outcome Measures:
  • Time from complete ear pain relief (score of 0 on FAECC or FPS-R) to a pain event using the home use data [ Time Frame: up to 4 Days (± 1) ] [ Designated as safety issue: No ]
    A pain event may include any or all of the following: analgesic/antipyretic use, a FAECC score ≥5 or FPS-R score ≥6, and study withdrawal due to AOM, treatment, or the study itself.

  • Relation between Analgesic/antipyretic use and study medication use during the In-Home Use period at or prior to 15, 30, and 60 minutes [ Time Frame: at or prior to 15, 30, and 60 minutes baseline study medication dose and up to 4 Days (± 1) ] [ Designated as safety issue: No ]
    Dates and times of analgesic/antipyretic use from will be compared with the dates and times of home use of study medication to create the use or non-use outcome for each time point.


Estimated Enrollment: 300
Study Start Date: December 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: AR01 - Topical Otic Solution

Topical ear drops

The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period

Drug: AR01
drops administered an needed for pain
Other Name: benzocaine
Placebo Comparator: Glycerin ear drops

Topical ear drops

The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period.

Drug: Glycerin ear drops
placebo drops administered for ear pain
Other Name: placebo

Detailed Description:

The study involves the initial clinic visit, using the ear drops at home and keeping a diary about the ear pain experienced and medications taken. The patient will return to the clinic 4 days later for evaluation and to return the ear drops and diary. The clinic staff will call to follow-up about the patient's condition seven days after the initial visit.

  Eligibility

Ages Eligible for Study:   2 Months to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects 2 mo. to < 19 yrs of age, with signs and symptoms of acute otitis media (AOM), with moderate to severe pain (current episode 2 wks duration). Moderate to severe pain is defined as a score of 5 (on a scale of 0 - 10) on the FAECC pain scale as evaluated by a trained clinical staff or 6 (on a scale of 0 - 10) on the FPS-R as evaluated by the subject. Moderate to severe pain criteria must be met at eligibility and the pre-dose pain assessment.
  • Males or non-pregnant, non-lactating females.
  • The subject's caregiver must have read and signed the written informed consent (including assent from subjects 18 yrs as applicable according to Investigational review board (IRB) guidelines) prior to study participation. Subjects 18 yrs old must have read and signed the written informed consent prior to study participation.
  • Normally active and otherwise judged to be in good health on the basis of medical history and limited physical examination.
  • Females of childbearing potential must have a urine pregnancy test at the randomization visit with negative results returned prior to randomization.

Exclusion Criteria

  • Perforated tympanic membrane, history of a perforated tympanic membrane in the last 6 months, or if a perforated tympanic membrane could not be ruled out by speculum examination, impedance testing tympanometry, pneumatic otoscopy, or Valsalva maneuver. Subjects who are subsequently diagnosed with a perforated membrane during treatment are to be discontinued immediately. Subjects with tympanostomy tubes are not allowed.
  • Acute or chronic otitis externa.
  • Chronic otitis media (refers to current episode 2 wks).
  • Seborrheic dermatitis involving the affected external ear canal or pinna.
  • Any otic, topical, or systemic antibiotic received within 14 days prior to study entry (topical or systemic antibiotics for acne will be allowed on a chronic basis for subjects who have been on a stable dose for at least 14 days prior to entry).
  • Any topical drying agent or over-the-counter therapy for otitis media received within 36 hrs prior to enrollment.
  • Known hypersensitivity to drug or similar compounds including any of the inactive ingredients.
  • Subjects receiving medication on a chronic basis for pain (including steroidal or non-steroidal anti-inflammatory drugs) who have not been on a stable dose for at least 1 month prior to entry into the study.
  • Clinically significant mental illness that may interfere with the conduct of the study (determined by Investigator).
  • Exposure to any investigational agent within 30 days prior to study entry.
  • Previous enrollment in this study.
  • Subject/caregiver has a condition the Investigator believes would interfere with the ability to provide consent or assent (age-appropriate) or comply with study instructions, or that might confound the interpretation of the study results, or put the subject at undue risk.
  • Subject has a glucose 6-phosphate dehydrogenase deficiency or is taking concomitant medications associated with methemoglobinemia (such as nitrates or nitrites; aniline dyes; or medications, including lidocaine, prilocaine, phenazopyridine hydrochloride [Pyridium], and others).
  • Subject shows clinical signs of anemia. The absolute amount of deoxygenated or abnormal hemoglobin (rather than its percentage) is required for cyanosis to be clinically evident. Subjects with moderate-to-severe anemia may not appear cyanotic, even with elevated percentages of deoxygenated or abnormal hemoglobins.
  • Subject has congenital (i.e., hereditary) methemoglobinemia.
  • Subject has a recent history of acute gastroenteritis within 14 days prior to study entry.
  • Subject exhibits clinical signs of methemoglobinemia, such as unexplained bluish coloring of skin, fatigue, shortness of breath, failure to thrive, and headache.
  • Subjects 5 to <19 yrs old who are unable to satisfactorily complete FPS-R screening test.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02074007

Locations
United States, Arizona
Clinical Research Consortium Arizona
Phoenix, Arizona, United States, 85004
United States, California
Madera Family Medical Group
Madera, California, United States, 93637
United States, Florida
Pharma Research International, Inc
Naples, Florida, United States, 34102
SCORE Physician Alliance, LLC
St. Petersburg, Florida, United States, 33710
United States, Kentucky
Kentucky Pediatric / Adult Research
Bardstown, Kentucky, United States, 40004
United States, Nebraska
Pioneer Clinical Research, LLC
Bellevue, Nebraska, United States, 68005
Omaha ENT Clinic
Omaha, Nebraska, United States, 68130
United States, New York
Children's Health Center / St. Elizabeth Medical Center
Utica, New York, United States, 13502
Valley Stream Pediatrics
Valley Stream, New York, United States, 11580
United States, North Carolina
Haywood pediatric and Adolescent Medicine Group, PA
Clyde, North Carolina, United States, 39721
United States, Ohio
Sterling Research Group, LTD
Cinncinati, Ohio, United States, 45246
Urgent Care Specialists Hometown Urgent Care
Columbus, Ohio, United States, 43214
Central Ohio Clinical Research
Columbus, Ohio, United States, 43207
United States, South Carolina
Carolina Ear, Nose & Throat Clinic
Orangeburg, South Carolina, United States, 29118
United States, Tennessee
PMG Research of Bristol
Bristol, Tennessee, United States, 37620
Holston Medical Group
Kingsport, Tennessee, United States, 37660
United States, Utah
Tanner Clinic
Layton, Utah, United States, 84041
Foothill Family Clinic South
Salt Lake City, Utah, United States, 84121
Heartland Research Associates LLC - Augusta
Salt Lake City, Utah, United States, 84121
United States, Virginia
Van Dorn Pediatrics
Alexandria, Virginia, United States, 22302
Sponsors and Collaborators
Arbor Pharmaceuticals, Inc.
Investigators
Study Chair: Laurence J Downey, MD Arbor Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: Arbor Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02074007     History of Changes
Other Study ID Numbers: AR01.007
Study First Received: January 16, 2014
Last Updated: June 23, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Arbor Pharmaceuticals, Inc.:
Acute Otitis Media
Pain
Ear Pain
Ear Ache
Ear infection
middle ear infection

Additional relevant MeSH terms:
Otitis
Otitis Media
Ear Diseases
Otorhinolaryngologic Diseases
Glycerol
Pharmaceutical Solutions
Cryoprotective Agents
Protective Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on August 01, 2014